Table 2.

Efficacy of nivolumab

NTumor response (95% CI)
Objective response rate (n = 34)1029% (16.8–46.2)
 Epithelioid (n = 27)726% (13.2–44.7)
 Biphasic (n = 4)125% (4.6–69.9)
 Sarcomatoid (n = 3)267% (20.8–93.9)
Disease control rate (n = 34)2368% (50.8–80.9)
Best overall response rate (n = 34)
 CR00% (0.0–10.2)
 PR1029% (16.8–46.2)
 SD1338% (23.9–55.0)
 PD926%
 NE26%
  • NOTE: All results are from the central assessment according to mRECIST. 95% CIs were calculated using the Wilson method; 95% CIs were not calculated for the PD or NE categories.